These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34754037)

  • 1. Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.
    Yokoi T; Oba T; Kajihara R; Abrams SI; Ito F
    Sci Rep; 2021 Nov; 11(1):21992. PubMed ID: 34754037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant
    Oba T; Kajihara R; Yokoi T; Repasky EA; Ito F
    Cancer Res; 2021 Dec; 81(24):6183-6195. PubMed ID: 34666993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multimodal Intralesional Therapy for Reshaping the Myeloid Compartment of Tumors Resistant to Anti-PD-L1 Therapy via IRF8 Expression.
    Patel A; Oba T; Kajihara R; Yokoi T; Abrams SI; Ito F
    J Immunol; 2021 Sep; 207(5):1298-1309. PubMed ID: 34362833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming primary and acquired resistance to anti-PD-L1 therapy by induction and activation of tumor-residing cDC1s.
    Oba T; Long MD; Keler T; Marsh HC; Minderman H; Abrams SI; Liu S; Ito F
    Nat Commun; 2020 Oct; 11(1):5415. PubMed ID: 33110069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer.
    Reguera-Nuñez E; Xu P; Chow A; Man S; Hilberg F; Kerbel RS
    J Exp Clin Cancer Res; 2019 Jan; 38(1):16. PubMed ID: 30635009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis.
    Chen C; Guo Q; Fu H; Yu J; Wang L; Sun Y; Zhang J; Duan Y
    Biomaterials; 2021 Aug; 275():120988. PubMed ID: 34186238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab for the treatment of triple-negative breast cancer.
    Heimes AS; Schmidt M
    Expert Opin Investig Drugs; 2019 Jan; 28(1):1-5. PubMed ID: 30474425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
    Zhou M; Luo C; Zhou Z; Li L; Huang Y
    J Control Release; 2021 Jun; 334():248-262. PubMed ID: 33915224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents.
    Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N
    Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral Plasmid IL12 Expands CD8
    Telli ML; Nagata H; Wapnir I; Acharya CR; Zablotsky K; Fox BA; Bifulco CB; Jensen SM; Ballesteros-Merino C; Le MH; Pierce RH; Browning E; Hermiz R; Svenson L; Bannavong D; Jaffe K; Sell J; Foerter KM; Canton DA; Twitty CG; Osada T; Lyerly HK; Crosby EJ
    Clin Cancer Res; 2021 May; 27(9):2481-2493. PubMed ID: 33593880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
    Zhang R; Yang Y; Dong W; Lin M; He J; Zhang X; Tian T; Yang Y; Chen K; Lei QY; Zhang S; Xu Y; Lv L
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35181605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade.
    Pilones KA; Hensler M; Daviaud C; Kraynak J; Fucikova J; Galluzzi L; Demaria S; Formenti SC
    Oncoimmunology; 2020 Oct; 9(1):1830524. PubMed ID: 33150045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapeutic IL-6R and targeting the MCT-1/IL-6/CXCL7/PD-L1 circuit prevent relapse and metastasis of triple-negative breast cancer.
    Haq ATA; Yang PP; Jin C; Shih JH; Chen LM; Tseng HY; Chen YA; Weng YS; Wang LH; Snyder MP; Hsu HL
    Theranostics; 2024; 14(5):2167-2189. PubMed ID: 38505617
    [No Abstract]   [Full Text] [Related]  

  • 16. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here.
    Kwa MJ; Adams S
    Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro-irradiated cancer vaccine enhances anti-tumor efficacy of radiotherapy and PD-L1 blockade in a syngeneic murine breast cancer model.
    Kim Y; Jeon SH; Kim S; Kang MH; Han MG; Lee SY; Kim IA
    Radiother Oncol; 2024 Nov; 200():110480. PubMed ID: 39159681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
    Raninga PV; Lee AC; Sinha D; Shih YY; Mittal D; Makhale A; Bain AL; Nanayakarra D; Tonissen KF; Kalimutho M; Khanna KK
    Int J Cancer; 2020 Jan; 146(1):123-136. PubMed ID: 31090219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.
    Liu HC; Viswanath DI; Pesaresi F; Xu Y; Zhang L; Di Trani N; Paez-Mayorga J; Hernandez N; Wang Y; Erm DR; Ho J; Susnjar A; Liu X; Demaria S; Chen SH; Teh BS; Butler EB; Xuan Chua CY; Grattoni A
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):492-506. PubMed ID: 32768562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.